Paradigm Biocapital Advisors LP Boosts Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Paradigm Biocapital Advisors LP lifted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 13.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 819,660 shares of the company’s stock after buying an additional 100,000 shares during the period. Oruka Therapeutics makes up 0.6% of Paradigm Biocapital Advisors LP’s portfolio, making the stock its 27th biggest position. Paradigm Biocapital Advisors LP owned about 2.34% of Oruka Therapeutics worth $15,893,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after purchasing an additional 1,572,853 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Oruka Therapeutics by 2,348.6% in the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company’s stock valued at $6,643,000 after acquiring an additional 328,434 shares during the period. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the fourth quarter worth about $54,000. Wellington Management Group LLP boosted its position in Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after purchasing an additional 12,952 shares during the last quarter. Finally, Barclays PLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at about $1,446,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ORKA shares. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research started coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and a consensus target price of $39.86.

Oruka Therapeutics Trading Down 1.3%

Shares of ORKA stock opened at $9.62 on Wednesday. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13. The stock has a market cap of $360.18 million, a P/E ratio of -1.54 and a beta of 0.25. The stock has a 50 day moving average of $9.93 and a 200 day moving average of $15.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.19. On average, research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the stock in a transaction on Friday, February 14th. The shares were bought at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the transaction, the insider now owns 4,148,428 shares of the company’s stock, valued at $47,458,016.32. This trade represents a 2.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 22.67% of the stock is owned by corporate insiders.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.